Liquidia Corp (LQDA) stock
Close on Nov 11, 2026Market cap $4.94BP/E –Yield –
Liquidia Corp grew revenue 798.4% to $621.87M over the twelve months to Sep 30, 2026. Free cash flow was $291.15M. At the latest close the market valued the company at $4.94B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $4.94B
- P/E ratio
- –
- Price to sales
- 7.95
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- 5.89%
Fundamentals
- Revenue
- $621.87M
- Net income
- -$94.19M
- EPS, diluted
- -$1.21
- Free cash flow
- $291.15M
- Book value per share
- -$0.28
- Diluted shares
- 90M
Trading
- Next earnings
- Mar 4, 2027 (estimated, before the open)
- Previous close
- $51.40
- Open
- $54.00
- Day's range
- $52.76 – $56.79
- Volume
- 3,874,194
- Average volume (20 days)
- 3,320,249
- Index membership
- S&P SmallCap 600, Russell 2000 (since Jun 2022), Russell 3000 (since Aug 2022)
- Beta (5 years)
- 0.95
- 52-week range
- $22.31 – $93.61
- RSI (14 days)
- 65.8
- Volatility (1 year)
- 92.7%
- Relative volume
- 1.34×
- WACC
- 9.6%
On 1 of our idea list: Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (SPSM, IJR, IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2020, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | LQDA | S&P 500 | Difference | LQDA per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +101.6% | -2.4% | +104.1 pts | ||
| 3 months | -37.3% | -1.2% | −36.1 pts | ||
| Year to date | +60.1% | +12.3% | +47.8 pts | ||
| 1 year | +98.7% | +12.4% | +86.3 pts | ||
| 3 years | +780.5% | +78.8% | +701.7 pts | +106.5% | +21.4% |
| 5 years | +967.9% | +75.2% | +892.7 pts | +60.6% | +11.9% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Liquidia filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- News
- News
- Results
About Liquidia
Pharmaceutical Preparations
Liquidia is a biopharmaceutical company that develops, manufactures, and commercializes treatments for patients with severe respiratory and vascular diseases, focusing on pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. The company’s primary offerings include Yutrepia, an inhaled dry-powder treprostinil therapy, and a generic treprostinil injection marketed in partnership with Sandoz. Liquidia promotes its products to healthcare professionals, notably pulmonologists and cardiologists, as well as specialty pharmacies and medical distributors.
Company profile, executives and historyLiquidia stock: common questions
What is Liquidia's stock price?
LQDA closed at $55.21 on Nov 11, 2026, up 7.41% on the day. Over the past 52 weeks it traded between $22.31 and $93.61.
What is Liquidia's market cap?
Liquidia was worth $4.94B at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is LQDA's P/E ratio?
Liquidia lost money over the twelve months to Sep 30, 2026 (diluted EPS -$1.21), so it has no meaningful P/E ratio.
How much revenue does Liquidia make?
Liquidia reported revenue of $621.87M for the twelve months to Sep 30, 2026, up 798.4% from a year earlier.
Does Liquidia pay a dividend?
No. Liquidia has not paid a cash dividend over the last twelve months.
When does Liquidia report earnings next?
Liquidia is expected to report Q4 FY2026 results on Mar 4, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has LQDA stock performed over the past year?
Including dividends, LQDA returned +98.7% over the past year, against +12.4% for the S&P 500.
How many LQDA shares are sold short?
18M shares were sold short at the latest FINRA report, 24.30% of the float, or 5.3 days of average trading volume.
Who are Liquidia's competitors?
Companies most similar to Liquidia by business, industry and size include MNKD, INVA, PHAR, KNSA, INSM.
See a number that looks wrong?